



**EUROPEAN
CURRICULUM**

VITAE FORMAT



PERSONAL INFORMATION

Name	MARIA VITTORIA DIECI
Address	University of Padova Department of Surgery, Oncology and Gastroenterology Istituto Oncologico Veneto IRCCS Division of Medical Oncology 2 Via Gattamelata 64 35128 Padova
Phone	+39-0498215949
Fax	+39 049-4225904
Email	mariavittoria.dieci@unipd.it mariavittoria.dieci@ioveneto.it
Nationality	Italian
Date of birth	December 4, 1982

**WORK/ACADEMIC
EXPERIENCE**

Dates (from-to)	February 2016 – present
Name of the employer	University of Padova Department of Surgery, Oncology and Gastroenterology Istituto Oncologico Veneto IRCCS Division of Medical Oncology 2
Occupation or position held	ASSISTANT PROFESSOR ATTENDING PHYSICIAN
Dates (from-to)	November 2013 – January 2016
Name of the employer	Division of Medical Oncology 2, Istituto Oncologico Veneto IRCCS Padova
Occupation or position held	MEDICAL ONCOLOGIST ON CONTRACT

Dates (from-to)	April 2014 – February 2016
Name of the employer	University of Padova Department of Surgery, Oncology and Gastroenterology Istituto Oncologico Veneto IRCCS
Occupation or position held	RESEARCH CONTRACT
Dates (from-to)	April 2014 – present
Name of the employer	University of Padova Department of Surgery, Oncology and Gastroenterology
Occupation or position held	PROFESSOR ON CONTRACT – didactic activity for the Specialization School in Medical oncology
Dates (from-to)	April 2012 –April 2014
Name of the employer	University of Modena and Reggio Emilia Department of Medical and Surgical Sciences of Mother, Child and Adult
Occupation or position held	RESEARCH FELLOW
Dates (from-to)	May 2012 – October-2013
Name of the employer	Gustave Roussy Institute, Villejuif (France)
Occupation or position held	VISITING RESEARCH FELLOW

EDUCATION AND TRAINING

Dates (from-to)	November 2012 - November 2013
Title of qualification awarded	DIPLOME UNIVERSITAIRE EUROPEEN DE RECHERCHE TRANSLATIONELLE ET CLINIQUE EN CANCEROLOGIE
Principal subjects/occupational skills covered	Translational research in breast cancer Title of final thesis : “Whole exome sequencing of rare aggressive breast cancer histologies: a help to discover novel pathways for breast cancer progression”
Name and type of organization providing education and training	Université Paris Sud Institut Gustave Roussy, Villejuif (France)
Dates (from-to)	13-18 march 2010
Title of qualification awarded	9TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY
Name and type of organization providing education and training	ESO-ESMO

Dates (from-to)	2008 - 2012
Title of qualification awarded	SPECIALIZATION IN MEDICAL ONCOLOGY, 110/110 cum Laude
Principal subjects/occupational skills covered	Title of the final thesis: "Discordance in biomarkers expression from primary to relapsed breast cancer: prognostic impact"
Name and type of organization providing education and training	University of Modena and Reggio Emilia
Dates (from-to)	2001 - 2007
Title of qualification awarded	MEDICAL DOCTOR, 110/110 cum Laude
Principal subjects/occupational skills covered	Title of the final thesis: "Modulation of biomarkers expression after neoadjuvant chemotherapy for operable breast cancer: prognostic and predictive value"
Name and type of organization providing education and training	Università degli studi di Modena e Reggio Emilia
GRANTS/AWARDS	<p>January 2015: 1° classified "BACK FROM SAN ANTONIO 2015 AWARD" for the nest published paper by a young oncologist in the year 2014: "<i>Prognostic value of tumor infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: A retrospective multicenter study</i>", Annals of Oncology 2014.</p> <p>November 2012: Monica Boscolo Research Grant 2012, project title: "Prognostic role of lymphocyte infiltrate in residual invasive disease after neoadjuvant therapy for HER2-positive and triple-negative breast cancer".</p>
SCIENTIFIC AFFILIATIONS	<p>AIOM (Associazione Italiana Oncologia medica) – member of the AIOM GIOVANI working group (2015-2017)</p> <p>ESMO (European Society of Medical Oncology)</p> <p>ASCO (American Society of Clinical Oncology)</p>
MOTHER TONGUE	Italian
OTHER LANGUAGES	English
Reading skills	EXCELLENT
Writing skills	EXCELLENT

Verbal skills	EXCELLENT June 2001: "Certificate Grade B" First Certificate in English (University of Cambridge Examinations Syndicate of Modena).
Reading skills	French EXCELLENT
Writing skills	EXCELLENT
Verbal skills	EXCELLENT
ANNEXES	Reviewer activity Publications Meetings

REVIEWER ACTIVITY

- Annals of Oncology
- The Oncologist
- PLOS ONE
- Journal of clinical pathology
- The Breast

PUBLICATIONS

Dr. Dieci is first or co-author of 31 publications published in peer-reviewed international journals with impact factor.

Total Impact Factor: 198,237 (JCR 2015)

H-index (Jan 2017, Scopus): 12

Dr Dieci is author of 6 book chapters and 3 other publications.

Publications in peer-reviewed journals with impact factor

1. Lefebvre C, Bachelot T, Filleron T, Pedrero M, Campone M, Soria JC, Massard C, Lévy C, Arnedos M, Lacroix-Triki M, Garrabey J, Boursin Y, Deloger M, Fu Y, Commo F, Scott V, Lacroix L, **Dieci MV**, Kamal M, Diéras V, Gonçalves A, Ferrero JM, Romieu G, Vanlemmens L, Mouret Reynier MA, Théry JC, Le Du F, Guiu S, Dalenc F, Clapisson G, Bonnefoi H, Jimenez M, Le Tourneau C, André F. Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis. PLoS Med. 2016 Dec 27;13(12):e1002201 (**IF 13.585**)
2. Griguolo G, **Dieci MV**, Giarratano T, Giorgi CA, Orvieto E, Ghiotto C, Berti F, Della Puppa A, Falci C, Mioranza E, Tasca G, Milite N, Miglietta F, Scienza R, Conte P, Guarneri V. Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome. J Neurooncol. 2016 Nov 16. [Epub ahead of print] (**IF 2.754**)
3. **Dieci MV**, Prat A, Tagliafico E, Paré L, Ficarra G, Bisagni G, Piacentini F, Generali DG, Conte P, Guarneri V. Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. Ann Oncol, 2016 Oct;27(10):1867-73 (**IF 9.269**)

4. Gennari R, Griguolo G, **Dieci MV**, Guarneri V, Tavaniello B, Sibilio A, Conte P. Fat grafting for breast cancer patients: From basic science to clinical studies. *Eur J Surg Oncol*. 2016 Aug;42(8):1088-102 (IF **2.940**)
5. Musolino N, Naldi N, **Dieci MV**, Zanoni D, Rimanti A, Boggiani D, Sgargi P, Generali D, Piacentini F, Ambroggi M, Cagossi K, Gianni L, Sarti S, Bisagni G, Ardizzoni A, Conte P, Guarneri V. Immunoglobulin G Fragment C Receptor Polymorphisms and Efficacy of Preoperative Chemotherapy plus Trastuzumab and Lapatinib in HER2-Positive Breast Cancer. *Pharmacogenomics J*, 2016 Oct;16(5):472-7. (IF **4.229**)
6. **Dieci MV**, Griguolo G, Miglietta F, Guarneri V. The immune system and hormone-receptor positive breast cancer: Is it really a dead end? *Cancer Treat Rev*. 2016 Mar 28;46:9-19. (IF **7.983**)
7. **Dieci MV**, Smutná V, Scott V, Yin G, Xu R, Vielh P, Mathieu MC, Vicier C, Laporte M, Drusch F, Guarneri G, Conte P, Delalogue S, Lacroix L, Fromigué O, André F, Lefebvre C. Whole exome sequencing of rare aggressive breast cancer histologies. *Breast Cancer Res Treat*, 2016 Feb;156(1):21-32. (IF **4.085**)
8. Guarneri V, **Dieci MV**, Frassoldati A, Maiorana A, Ficarra G, Bettelli S, Tagliafico E, Biciato S, Generali DG, Cagossi K, Bisagni G, Sarti S, Musolino A, Ellis C, Crescenzo R, Conte PF. Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer. *The Oncologist*. 2015 Sep;20(9):1001-10. (IF **4.789**)
9. **Dieci MV**, Mathieu MC, Guarneri V, Conte P, Delalogue S, Andre F, Goubar A. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. *Ann Oncol*. 2015 Aug;26(8):1698-704. (IF **9.269**)
10. Guarneri V, **Dieci MV**, Bisagni G, Boni C, Cagossi K, Puglisi F, Pecchi A, Piacentini F, Conte P. Preoperative Carboplatin-Paclitaxel-Bevacizumab in Triple-Negative Breast Cancer: Final Results of the Phase II Ca.Pa.Be Study. *Ann Surg Oncol*. 2015 Jan 9. [Epub ahead of print] (IF **3.655**)
11. Vicier C, **Dieci MV**, Arnedos M, Delalogue S, Viens P, Andre F. Clinical Development of mTOR inhibitors in breast cancer. *Breast Cancer Res*. 2014 Feb 17;16(1):203. (IF **5.211**)
12. **Dieci MV**, Piacentini F, Dominici M, Omarini C, Goubar A, Ficarra G, Conte P, Guarneri V. Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact. *Anticancer Res*. 2014 Jul;34(7):3657-62. (IF **1.895**)
13. **Dieci MV**, Orvieto E, Dominici M, Conte P, Guarneri V. Rare breast cancer subtypes: histological, molecular, and clinical peculiarities. *Oncologist*. 2014 Aug;19(8):805-13. (IF **4.789**)
14. Falci C, **Dieci MV**, Guarneri V, Soldà C, Bria E, Tortora G, Conte P. Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents. *Expert Rev Anticancer Ther*. 2014 Sep;14(9):1041-50. (IF **2.094**)
15. **Dieci MV**, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delalogue S, Curigliano G, Andre F. Prognostic value of tumor infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: A retrospective multicenter study. *Ann Oncol* 2014 Mar;25(3):611-8. (IF: **9.269**)
16. Vicier C, **Dieci MV**, Andre F. New strategies to overcome resistance to mammalian target of rapamycin inhibitors in breast cancer. *Curr Opin Oncol*. 2013 Nov;25(6):587-93. (IF **4.614**)
17. Alsafadi S, Even C, Falet C, Goubar A, Commo F, Scott V, Quidville V, Albiges L, **Dieci MV**, Guegan J, Lazar V, Ahomadegbe JC, Delalogue S, André F. Retinoic Acid receptor alpha amplifications and retinoic Acid sensitivity in breast cancers. *Clin Breast Cancer*. 2013 Oct;13(5):401-8. (IF **3.082**)
18. Guarneri V, **Dieci MV**, Barbieri E, Piacentini F, Omarini C, Ficarra G, Bettelli S, Conte PF. Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. *Ann Oncol*. 2013 Dec;24(12):2990-4. (IF **9.269**)
19. Guarneri V, **Dieci MV**, Conte P. Relapsed triple-negative breast cancer: challenges and treatment strategies. *Drugs*. 2013 Aug;73(12):1257-65. (IF **4.883**)
20. **Dieci MV**, Arnedos M, Delalogue S, Andre F. Quantification of residual risk of relapse in breast cancer patients optimally treated. *Breast*. 2013 Aug 1;22S2:S92-S95. (IF **2.740**)

21. **Dieci MV**, Arnedos M, Andre F, Soria JC. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. *Cancer Discov.* 2013 Mar;3(3):264-79. (IF 19.783)
22. Dogan S, **Dieci MV**, Goubar A, Arnedos M, Delaloge S, Andre F. Landscape and evolution of therapeutic research for breast cancer patients. *Breast Cancer Res Treat.* 2013 Feb;138(1):319-24. (IF 4.085)
23. **Dieci MV**, Barbieri E, Piacentini F, Ficarra G, Bettelli S, Dominici M, Conte PF, Guarneri V. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis. *Ann Oncol.* 2013 Jan;24(1):101-8. (IF 9.269)
24. Andre F, **Dieci MV**, Dubsky P, Sotiriou C, Curigliano G, Denkert C, Loi S. Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. *Clin Cancer Res.* 2013 Jan 1;19(1):28-33. (IF 8.738)
25. **Dieci MV**, Barbieri E, Bettelli S, Piacentini F, Omarini C, Ficarra G, Balduzzi S, Dominici M, Conte P, Guarneri V. Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. *J Clin Pathol.* 2012 Jun;65(6):503-6. (IF 2.912)
26. Guarneri V, **Dieci MV**, Conte P. Enhancing intracellular taxanes delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. *Expert Opin Pharmacother* 2012 Feb;13(3):395-406. (IF 3.543)
27. Maur M, Tomasello C, Frassoldati A, **Dieci MV**, Barbieri E, Conte P. Posterior Reversible Encephalopathy Syndrome During Ipilimumab Therapy for Malignant Melanoma. *J Clin Oncol* 2012 Feb 20;30(6):e76-8. (IF 20.982)
28. Guarneri V, Pecchi A, Piacentini F, Barbieri E, **Dieci MV**, Ficarra G, Tazzioli G, Frassoldati A, Battista R, Canossi B, Mauri C, D'Amico R, Conte P, Torricelli P. Magnetic resonance imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in stage II-III breast cancer. *Ann Surg Oncol* 2011 Aug;18(8):2150-7. (IF 3.655)
29. Guarneri V, Barbieri E, **Dieci MV**, Piacentini F, Conte P. Timing for starting second-line therapy in recurrent ovarian cancer. *Expert Rev Anticancer Ther* 2011 Jan;11(1):49-55. (IF 2.094)
30. Guarneri V, Barbieri E, **Dieci MV**, Piacentini F, Conte P. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. *Cancer Treat Rev.* 2010 Nov;36S3:S62-S66. (IF 7.983)
31. Guarneri V, Giovannelli S, Ficarra G, Bettelli S, Maiorana A, Piacentini F, Barbieri E, **Dieci MV**, D'Amico R, Jovic G, Conte P. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. *Oncologist*, 2008 Aug; 13(8):838-44. (IF 4.789)

Book chapters

1. De Laurentiis M, De Placido S, Bianco AR, **Dieci MV**, Guarneri V: Carcinoma della Mammella. In "Core Curriculum. Oncologia Clinica", Ed. 2 2015, pp 155-184, Milano: Mc-Graw-Hill. ISBN 8838639841
2. Lauria R, Forestieri V, Baretta Z, **Dieci MV** : Tumori ginecologici. In "Core Curriculum. Oncologia Clinica", Ed. 2 2015, pp 253-269, Milano: Mc-Graw-Hill. ISBN 8838639841
3. Pepe S, Pensabene M, Condello C, Contegiacomo A, Zovato S, **Dieci MV**. Tumori eredo-familiari. In "Core Curriculum. Oncologia Clinica", Ed. 2, 2015, pp 135-154, Milano: Mc-Graw-Hill. ISBN 8838639841
4. **Dieci MV**, Guarneri V, Giorgi CA, Conte PF: Targeted therapies for HER2-positive breast cancer. In: Russo A, Rosell R, Rolfo C, "Targeted therapies for solid tumors", 2015, pp 57-72, Springer Science + Business media New York. ISBN: 9781493920464
5. **Dieci MV**, Andre F: Targeting the Fibroblast Growth Factor Receptor Pathway in Human Cancer. In: Giaccone G and Soria JC, "Targeted Therapies in Oncology". Second edition, 2013, p. 157-172, CRC Press, Taylor and Francis group, ISBN: 978-1842145456

6. Conte P, Barbieri E, Guarneri V, Piacentini F, **Dieci MV**: Tumori ginecologici. In: R. Cellerino, G Cetto, A Piga. "Oncologia Clinica Principi e Pratica". 2012, vol. Vol 4, p. 1-83, Rozzano (MI): CEA (Casa Editrice Ambrosiana) Selecta Medica, ISBN/ISSN: 9788808182593

Other publications:

1. Evangelista L, **Dieci MV**, Guarneri V, Conte PF. 18F-Fluoroestradiol Positron Emission Tomography In Breast Cancer Patients: Systematic Review Of The Literature & Meta-Analysis Curr Radiopharm. 2016 Oct 19. [Epub ahead of print]
2. **Dieci MV**, Guarneri V. PIK3CA: a Target or a Marker in Breast Cancers. Curr Breast Cancer Rep. Published online on 4 July 2015.
3. **Dieci MV**, Guarneri V, Conte P. The future of chemotherapy in the era of personalized medicine. Curr Breast Cancer Rep. 2013;5:57-68.

Abstracts

Dr. Dieci is author of more than 30 abstracts presented at international and national meetings:

PARTICIPATION TO NATIONAL AND INTERNATIONAL MEETINGS, INVESTIGATOR MEETINGS AND COURSES

Dr Dieci has participated in more than 80 international and national meetings, conferences and symposia as presenter or attendant (oral communications/presentations and poster presentations at more than 45 meetings).